nisoldipine has been researched along with Disease Models, Animal in 8 studies
Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.
nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.
methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to investigate the effectiveness of nisoldipine, an L-type voltage-sensitive calcium channel blocker, to ameliorate anxiety and fear response in a mouse model of post-traumatic stress disorder (PTSD)." | 3.83 | Investigating the role of nisoldipine in foot-shock-induced post-traumatic stress disorder in mice. ( Bali, A; Jaggi, AS; Singh, N; Verma, M, 2016) |
| "Hypertrophic cardiomyopathy is associated with disorganization of cytoskeletal proteins and altered energy metabolism." | 1.43 | The L-type Ca(2+) channel facilitates abnormal metabolic activity in the cTnI-G203S mouse model of hypertrophic cardiomyopathy. ( Cserne Szappanos, H; Filipovska, A; Hool, L; Johnstone, V; Richman, T; Semsarian, C; Tsoutsman, T; Viola, H, 2016) |
| "Treatment with nisoldipine induces a beneficial effect by reduction of infarct size in repeated coronary reperfusion." | 1.30 | Beneficial effect of nisoldipine in repeated coronary reperfusion. ( Hammerman, H; Hir, J; Moscovitz, M, 1997) |
| "Nisoldipine was administered to the hearts before 60 minutes of global ischemia." | 1.29 | Improvement of ischemic myocardial dysfunction by nisoldipine. ( Itakura, A; Saida, K; Umeda, M, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Mundada, VP | 1 |
| Patel, MH | 1 |
| Mundada, PK | 1 |
| Sawant, KK | 1 |
| Verma, M | 1 |
| Bali, A | 1 |
| Singh, N | 1 |
| Jaggi, AS | 1 |
| Viola, H | 1 |
| Johnstone, V | 1 |
| Cserne Szappanos, H | 1 |
| Richman, T | 1 |
| Tsoutsman, T | 1 |
| Filipovska, A | 1 |
| Semsarian, C | 1 |
| Hool, L | 1 |
| Saida, K | 1 |
| Umeda, M | 1 |
| Itakura, A | 1 |
| Rosenthal, T | 1 |
| Grossman, E | 1 |
| Mori, T | 1 |
| Ishigai, Y | 1 |
| Fukuzawa, A | 1 |
| Chiba, K | 1 |
| Shibano, T | 1 |
| Hammerman, H | 1 |
| Moscovitz, M | 1 |
| Hir, J | 1 |
8 other studies available for nisoldipine and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Enhanced bioavailability and antihypertensive activity of nisoldipine loaded nanoemulsion: optimization, cytotoxicity and uptake across Caco-2 cell line, pharmacokinetic and pharmacodynamic studies.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Biological Availability; Caco-2 Cells; Disea | 2020 |
Investigating the role of nisoldipine in foot-shock-induced post-traumatic stress disorder in mice.
Topics: Animals; Anxiety; Behavior, Animal; Corticosterone; Disease Models, Animal; Electroshock; Mice; Moto | 2016 |
The L-type Ca(2+) channel facilitates abnormal metabolic activity in the cTnI-G203S mouse model of hypertrophic cardiomyopathy.
Topics: Actins; Animals; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Cardiomyopathy, Hypert | 2016 |
Improvement of ischemic myocardial dysfunction by nisoldipine.
Topics: Animals; Coronary Vessels; Disease Models, Animal; Heart; Heart Rate; L-Lactate Dehydrogenase; Male; | 1994 |
Nisoldipine for hypertension.
Topics: Animals; Disease Models, Animal; Humans; Hypertension; Hypertension, Renovascular; Nisoldipine; Rats | 1994 |
Pharmacological profile of semotiadil fumarate, a novel calcium antagonist, in rat experimental angina model.
Topics: Acetylcholine; Angina Pectoris; Animals; Arginine Vasopressin; Calcium Channel Blockers; Coronary Ve | 1995 |
Beneficial effect of nisoldipine in repeated coronary reperfusion.
Topics: Animals; Calcium Channel Blockers; Coronary Disease; Disease Models, Animal; Dogs; Hemodynamics; Inf | 1997 |